Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab as Bridge to Allo-HSCT in High Risk Precursor B-ALL
NCT05559450Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall Survival at 720 days. Started Feb 2022; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05559450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559450.